کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10165110 | 1177123 | 2014 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ANPACECNPBNPHFpEFLVEFNYHANT-proBNPHFrEFAngiotensin-converting enzyme - آنژیوتانسین تبدیل آنزیمNew York Heart Association - انجمن قلب نیویورکconfidence interval - فاصله اطمینانHeart failure with preserved ejection fraction - نارسایی قلب با کسر خروجی حفظ شدهheart failure - نارسایی قلبیheart failure with reduced ejection fraction - نارسایی قلبی با کاهش کسر تخلیهhazard ratio - نسبت خطرNeprilysin - نپریلینNatriuretic peptide - پپتید NatriureticC-type natriuretic peptide - پپتید سدیم نوعی پتاسیمatrial natriuretic peptide - پپتید نایروئیدوری دهلیزleft ventricular ejection fraction - کسر خروجی بطن چپ
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure](/preview/png/10165110.png)
چکیده انگلیسی
Neprilysin is an enzyme that contributes to the breakdown of the biologically active natriuretic peptides and several other vasoactive compounds. Inhibiting neprilysin has been a therapeutic target for several compounds that have been tested in cardiovascular disease, including ecadotril, candoxatril, omapatrilat, and LCZ696. Although ecadotril, candoxatril, and omapatrilat were initially tested in hypertension and/or heart failure, lack of efficacy and side effects led to discontinuation of their development. LCZ696 (sacubitril valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that has been developed for use in heart failure. This compound is composed of 2 molecular moieties in a single crystalline complex-the angiotensin receptor blocker valsartan and a neprilysin inhibitor prodrug-and has now been tested in hypertension, in a phase 2 trial in heart failure with preserved ejection fraction, and has demonstrated greater efficacy than enalapril in a phase 3 trial in heart failure with reduced ejection fraction. Its ability to inhibit the renin-angiotensin-aldosterone axis and augment the endogenous natriuretic peptide system provides a distinctive mechanism of action in cardiovascular disease.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: JACC: Heart Failure - Volume 2, Issue 6, December 2014, Pages 663-670
Journal: JACC: Heart Failure - Volume 2, Issue 6, December 2014, Pages 663-670
نویسندگان
Orly PharmD, MS, Ryan BS, Scott D. MD,